Dear Editor
Patients with moderate‐to‐severe atopic dermatitis (AD) or psoriasis often require systemic immunomodulatory therapy. The uncertainty of the potential of these therapies to increase the risk of more serious illness due to coronavirus disease 2019 (COVID‐19) may have caused anxiety and led to treatment discontinuation. Therefore, we conducted an anonymous questionnaire on concerns of COVID‐19 in patients with AD or psoriasis treated with systemic immunomodulatory therapy.
Adult AD and psoriasis patients with an outpatient visit at the Department of Dermatology at Aarhus University Hospital or Gentofte Hospital, Denmark, between 2 April 2020 and 15 June 2020 were invited to participate. We assessed whether patients were concerned about becoming ill with COVID‐19 due to their disease and/or their systemic immunomodulatory therapy and whether patients discontinued their treatment during the COVID‐19 pandemic.
A total of 301 adult patients including 68 with AD and 233 with psoriasis completed the questionnaire. Of these, 35.7% were female and 24.5% were ≥60 years old (Table 1). The most common comorbidities were hay fever (69.1%) and asthma (60.3%) among AD patients, and psoriatic arthritis (32.6%) and cardiovascular diseases (18.0%) among psoriasis patients. Patients felt to a great extent well treated (67.0%) and safe about their treatment in general (76.4%).
Table 1.
Baseline demographics
|
Patients with atopic dermatitis n = 68 |
Patients with psoriasis n = 233 |
All patients n = 301 |
|
|---|---|---|---|
| Female, n (%) | 31 (46.3) | 74 (32.6) | 105 (35.7) |
| Age, n (%) | |||
| 18–29 years | 15 (22.1) | 27 (11.7) | 42 (14.1) |
| 30–39 years | 10 (14.7) | 38 (16.5) | 48 (16.1) |
| 40–49 years | 19 (27.9) | 49 (21.2) | 68 (22.7) |
| 50–59 years | 12 (17.7) | 56 (24.2) | 68 (22.7) |
| 60–69 years | 6 (8.8) | 43 (18.6) | 49 (16.4) |
| 70–79 years | 5 (7.4) | 17 (7.4) | 22 (7.4) |
| 80–89 years | 1 (1.5) | 1 (0.4) | 2 (0.7) |
| Smoking status, n (%) | |||
| Current smoker | 19 (28.4) | 60 (26.0) | 79 (26.5) |
| Prior smoker | 18 (26.9) | 109 (47.2) | 127 (42.6) |
| Never smoker | 30 (44.8) | 62 (26.8) | 92 (30.9) |
| Comorbidities, n (%) | |||
| Hay fever | 47 (69.1) | 32 (13.7) | 79 (26.3) |
| Asthma | 41 (60.3) | 25 (10.7) | 66 (21.9) |
| COPD | 5 (7.4) | 7 (3.0) | 12 (4.0) |
| Diabetes | 2 (2.9) | 29 (12.5) | 31 (10.3) |
| Cardiovascular diseases | 9 (13.2) | 42 (18.0) | 51 (16.9) |
| Cancer (ex. skin cancer) | 1 (1.5) | 8 (3.4) | 9 (3.0) |
| Psoriatic arthritis | — | 76 (32.6) | — |
| Type of treatment, n (%)† | |||
| Conventional systemics | 38 (55.9) | 114 (48.9) | 152 (52.5) |
| Prednisolone | 12 (17.7) | 0 | 12 (4.0) |
| Biologics | 30 (44.1) | 155 (66.5) | 185 (61.5) |
| Duration of treatment, n (%) | |||
| <12 months | 30 (44.1) | 59 (25.3) | 89 (29.6) |
| ≥12 months | 38 (55.9) | 174 (74.7) | 212 (70.4) |
| Feeling disease being well treated, n (%) | |||
| To a great extent | 36 (55.4) | 163 (70.3) | 199 (67.0) |
| To some extent | 18 (27.7) | 57 (24.6) | 75 (25.3) |
| To a lesser extent | 10 (15.4) | 10 (4.3) | 20 (6.7) |
| Not at all | 1 (1.5) | 2 (0.9) | 3 (1.0) |
| Feeling safe about treatment, n (%) | |||
| To a great extent | 37 (56.9) | 190 (81.9) | 227 (76.4) |
| To some extent | 24 (36.9) | 36 (15.5) | 60 (20.2) |
| To a lesser extent | 3 (4.6) | 6 (2.6) | 9 (3.0) |
| Not at all | 1 (1.5) | 0 | 1 (0.3) |
COPD, chronic obstructive pulmonary disease; COVID‐19, coronavirus disease 2019; ex, excluding.
Some patients used more than one of the three types of therapies.
We found that 52.7% were concerned about becoming ill with COVID‐19 due to their skin disease and 68.0% due to their treatment, respectively, and 7.3% discontinued their treatment. No differences were observed for age, type of treatment or treatment duration, but female patients were more concerned about becoming ill with COVID‐19 due to their treatment than male patients (Table 2). AD patients with asthma were more concerned about becoming ill with COVID‐19 due to their AD and treatment, whereas psoriasis patients with psoriatic arthritis were more concerned about becoming ill due to psoriasis (Table 2). Further, patients who in general felt unsafe about their treatment were more concerned about becoming ill with COVID‐19 (P < 0.01) and were more likely to discontinue their treatment during the COVID‐19 pandemic (P = 0.018).
Table 2.
Proportion of patients concerned due to COVID‐19 and discontinuing treatment during the COVID‐19 pandemic
| Patients concerned of their skin disease due to COVID‐19 | Patients concerned of treatment due to COVID‐19 | Patients discontinued treatment during COVID‐19 pandemic | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Yes | No | P‐value | Yes | No | P‐value | Yes | No | P‐value | |
| n = 159 | n = 142 | n = 205 | n = 96 | n = 22 | n = 279 | ||||
| Sex, n (%) | |||||||||
| Female | 62 (39.7) | 43 (31.2) | 0.13 | 80 (39.8) | 25 (26.9) | 0.032 | 10 (45.5) | 95 (34.9) | 0.32 |
| Male | 94 (60.3) | 95 (68.8) | 121 (60.2) | 68 (73.1) | 12 (54.5) | 177 (65.1) | |||
| Age, n (%) | |||||||||
| <60 years | 123 (77.4) | 105 (73.9) | 0.49 | 154 (75.1) | 74 (77.1) | 0.71 | 19 (86.4) | 209 (74.9) | 0.23 |
| ≥60 years | 36 (22.6) | 37 (26.1) | 51 (24.9) | 22 (22.9) | 3 (13.6) | 70 (25.1) | |||
| Type of treatment, n (%) | |||||||||
| Biologics | 103 (64.8) | 82 (57.8) | 0.21 | 133 (64.9) | 52 (54.2) | 0.08 | 11 (50.0) | 174 (62.4) | 0.25 |
| Systemics | 85 (53.5) | 67 (47.2) | 0.28 | 106 (51.7) | 46 (47.9) | 0.54 | 13 (59.1) | 139 (49.8) | 0.4 |
| Prednisolone | 9 (5.7) | 3 (2.1) | 0.12 | 9 (4.4) | 3 (3.1) | 0.6 | 1 (4.6) | 11 (3.9) | 0.75 |
| Duration of treatment, n (%) | |||||||||
| <12 months | 48 (30.2) | 41 (28.9) | 0.8 | 63 (30.7) | 26 (27.1) | 0.52 | 6 (27.3) | 83 (29.8) | 0.81 |
| ≥12 months | 111 (69.8) | 101 (71.1) | 142 (69.3) | 70 (72.9) | 16 (72.7) | 196 (70.3) | |||
| Precautions during COVID‐19, n (%) | |||||||||
| All precautions | 133 (83.7) | 65 (45.8) | <0.0001 | 161 (78.5) | 37 (38.5) | <0.0001 | — | — | — |
| Sought advice | 98 (61.6) | 51 (35.9) | <0.0001 | 119 (58.1) | 30 (31.3) | <0.0001 | 15 (68.2) | 134 (48.0) | 0.07 |
| Discontinued treatment | 6 (10.1) | 16 (4.2) | 0.052 | 20 (9.8) | 2 (2.1) | 0.017 | — | — | — |
| Social isolation | 70 (44.0) | 27 (19.0) | <0.0001 | 88 (42.9) | 9 (9.4) | <0.0001 | 11 (50.0) | 86 (30.8) | 0.06 |
| Comorbidities, n (%) | |||||||||
| Hay fever† | 33 (75.0) | 14 (58.3) | 0.16 | 27 (39.7) | 20 (29.4) | 0.27 | 2 (66.7.1) | 45 (69.2) | 0.93 |
| Asthma† | 32 (72.7) | 9 (37.5) | 0.0046 | 26 (72.2) | 15 (46.9) | 0.033 | 3 (100) | 38 (58.5) | 0.15 |
| COPD | 8 (5.0) | 4 (2.8) | 0.33 | 10 (4.9) | 2 (2.1) | 0.25 | 4 (18.2) | 8 (2.9) | 0.0004 |
| Diabetes | 16 (10.1) | 15 (10.6) | 0.89 | 19 (9.3) | 12 (12.5) | 0.39 | 4 (18.2) | 27 (9.7) | 0.21 |
| Cardiovascular diseases | 25 (15.7) | 26 (18.3) | 0.55 | 31 (15.1) | 20 (20.8) | 0.22 | 4 (18.2) | 47 (16.9) | 0.87 |
| Cancer (ex. skin cancer) | 4 (2.5) | 5 (3.5) | 0.61 | 4 (2.0) | 5 (5.2) | 0.12 | 0 (0) | 9 (3.2) | 0.39 |
| Psoriatic arthritis† | 51 (41.5) | 25 (22.7) | 0.0023 | 58 (36.0) | 18 (25.0) | 0.09 | 8 (42.1) | 68 (31.8) | 0.36 |
| Feeling disease being well treated, n (%) | |||||||||
| Yes, to a great extent | 102 (64.2) | 97 (68.3) | 0.45 | 133 (64.9) | 66 (68.8) | 0.51 | 8 (36.4) | 191 (68.5) | 0.0022 |
| Feeling safe about treatment, n (%) | |||||||||
| Yes, to a great extent | 108 (67.9) | 119 (83.8) | 0.0014 | 141 (68.8) | 86 (89.6) | <0.0001 | 12 (54.6) | 215 (77.1) | 0.018 |
| COVID‐19 symptoms, n (%) | |||||||||
| Yes, having symptoms | 32 (21.7) | 17 (14.3) | 0.12 | 40 (21.6) | 9 (11.1) | 0.042 | 9 (40.9) | 40 (16.4) | 0.0045 |
COPD, chronic obstructive pulmonary disease; COVID‐19, coronavirus disease 2019; ex, excluding.
P‐values < 0.05 are marked in bold.
Only patients with atopic dermatitis. ‡Only patients with psoriasis.
Fear of serious consequences of COVID‐19 infection might lead patients to discontinue treatment without consulting a dermatologist. An Italian study found 5.2% of 515 psoriasis patients treated with biologics discontinued therapy by themselves. 1 We found 7.3% patients discontinued their therapy. Interestingly, as Denmark has a low proportion of COVID‐19 cases, treatment discontinuation could be driven by media‐induced fear instead of COVID‐19 infections. Indeed, patients who discontinued treatment felt less safe with their treatment in general, highlighting the need of identifying these patients and informing them accordingly. More than half the patients found themselves concerned about becoming ill with COVID‐19 due to their disease and/or their treatment. This could be attributed to comorbidities related to increased risk for severe COVID‐19 infection, e.g. asthma in AD patients and conflicting information regarding COVID‐19. During the early phases of the COVID‐19 pandemic, experts disagreed on how to act regarding immunomodulatory therapy. 2 , 3 , 4 Since then, studies have not found an increased risk of serious consequences of COVID‐19 infection in AD or psoriasis patients treated with immunomodulatory therapies. 5 , 6 , 7 These therapies may even have a protective role against the cytokine storm seen in critical cases of COVID‐19. 8 Currently, trials for targeted immunomodulatory therapies investigating the efficacy in COVID‐19 are undergoing, 9 and dexamethasone has already shown promising results. 10 Some limitations should be considered, e.g. the self‐reported nature of the study and that only patients with an outpatient visit at the department of dermatology were included resulting in risk of selection bias. In conclusion, identifying and informing patients feeling unsafe with treatment is important as this might avoid unnecessary treatment discontinuations.
Funding sources
There was no funding for the study.
Conflict of interest
Halling and Loft had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Skov and Thyssen. Acquisition, analysis, and interpretation of data: All authors. Drafting of the manuscript: Halling and Loft. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Loft. Administrative, technical, or material support: None.
References
- 1. Burlando M, Carmisciano L, Cozzani E, Parodi A. A survey of psoriasis patients on biologics during COVID‐19: a single centre experience. J Dermatol Treat 2020;1–1. [DOI] [PubMed] [Google Scholar]
- 2. Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I. COVID‐19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action [Published online ahead of print, 2020 Mar 11]. Dermatol Ther 2020; e13298. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Lebwohl M, Rivera‐Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID‐19? J Am Acad Dermatol 2020; 82: 1217–1218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Ricardo JW, Lipner SR. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID‐19 pandemic [Published online ahead of print, 2020 Mar 27]. Dermatol Ther 2020; e13687. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Gisondi P, Facheris P, Dapavo P et al. The impact of COVID‐19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience. Br J Dermatol 2020; 183: 373–374. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Fougerousse AC, Perrussel M, Bécherel PA et al. Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID‐19 [Published online ahead of print, 2020 Jun 21]. J Eur Acad Dermatol Venereol 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Carugno A, Raponi F, Locatelli A et al. No evidence of increased risk for coronavirus disease 2019 (COVID‐19) in patients treated with dupilumab for atopic dermatitis in a high‐epidemic area‐Bergamo, Lombardy, Italy [Published online ahead of print, 2020 Apr 27]. J Eur Acad Dermatol Venereol. 10.1111/jdv.16552 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Schett G, Sticherling M, Neurath MF. COVID‐19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol 2020; 20: 271–272. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Eli Lily and Company . A Study of Baricitinib (LY3009104) in Participants With COVID‐19 (COV‐BARRIER) (NCT04421027). URL https://clinicaltrials.gov/ct2/show/NCT04421027?term=baricitinib&draw=2&rank=16 (last accessed: 1 July 2020).
- 10. Oxford University News Release, Low‐cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID‐19. URL https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf (last accessed: 24 June 2020).